Understanding Immunotherapy for Blood Cancer: A Patient Guide

If your oncologist has mentioned immunotherapy as a treatment option, you are far from alone. Over the past decade, immunotherapy has transformed the treatment landscape for blood cancers like leukemia, lymphoma, and multiple myeloma. These therapies work differently from traditional chemotherapy — rather than attacking cancer cells with chemicals, they harness the power of your own immune system to recognize and destroy them. Understanding how these treatments work and what they involve can help you feel more prepared and empowered as you navigate your care plan.

How Immunotherapy Differs from Traditional Chemotherapy

Chemotherapy works by targeting rapidly dividing cells throughout the body, which is why it affects both cancerous and healthy cells and causes the familiar range of side effects. Immunotherapy takes a fundamentally different approach. Instead of directly killing cancer cells, these treatments enhance, redirect, or retrain your immune system so it can identify and attack the cancer more effectively on its own. For many blood cancer patients, immunotherapy offers the possibility of deep and durable remissions — sometimes even when previous treatments have stopped working.

Types of Immunotherapy for Blood Cancer

There are several categories of immunotherapy currently used to treat blood cancers, and your oncologist may recommend one or more depending on your diagnosis, treatment history, and individual health profile.

Monoclonal Antibodies

Monoclonal antibodies are laboratory-created proteins designed to bind to specific targets on cancer cells. Some mark cancer cells so your immune system can find and destroy them more easily. Others carry toxic substances directly to the cancer cell or block signals that help the cancer grow. Rituximab, one of the most widely used monoclonal antibodies, has been a cornerstone of lymphoma treatment for more than two decades. These therapies are typically administered through intravenous infusion in an outpatient setting over several weeks.

CAR-T Cell Therapy

CAR-T cell therapy is one of the most significant advances in blood cancer treatment. In this approach, T cells — a type of white blood cell that fights infection — are collected from your blood and sent to a laboratory where they are genetically modified to produce chimeric antigen receptors. These receptors allow the T cells to recognize specific markers on your cancer cells. The engineered cells are multiplied and then infused back into your body, where they seek out and destroy the cancer. CAR-T therapy has achieved remarkable remission rates in patients with certain types of leukemia, lymphoma, and multiple myeloma, including those whose cancer had not responded to other treatments.

Because CAR-T therapy involves a complex manufacturing process, there is typically a waiting period of several weeks between cell collection and infusion. Patients generally need to stay in or near the hospital for monitoring after the infusion, as the therapy can cause significant side effects. If you are preparing for an intensive treatment that requires an extended stay, our guide to <a href="/blog/preparing-for-stem-cell-transplant-blood-cancer-guide">preparing for a stem cell transplant</a> covers many of the same logistical considerations.

Bispecific Antibodies

Bispecific antibodies are a newer class of immunotherapy gaining ground rapidly in blood cancer care. These engineered proteins bind to two different targets at once — typically a marker on the cancer cell and a receptor on your T cells. By physically bringing the T cell and the cancer cell together, bispecific antibodies help your immune system attack cancer more precisely. Several bispecific antibodies have been approved for treating lymphoma and multiple myeloma, with more in clinical development. Your oncologist can tell you whether any of these therapies are appropriate for your situation.

Checkpoint Inhibitors

Cancer cells sometimes evade the immune system by activating molecular "brakes" called checkpoints on T cells. Checkpoint inhibitor drugs release those brakes, allowing your immune system to recognize and fight the cancer. While checkpoint inhibitors are more commonly associated with solid tumors, they play a role in treating certain blood cancers as well, including Hodgkin lymphoma. Your care team will discuss whether this approach makes sense for your specific diagnosis.

Side Effects and What to Expect During Immunotherapy

Every type of immunotherapy carries its own side effect profile, and your medical team will monitor you closely throughout treatment. One of the most discussed side effects of CAR-T cell therapy is cytokine release syndrome, which occurs when activated immune cells release large amounts of signaling molecules called cytokines. Symptoms can include fever, chills, low blood pressure, nausea, fatigue, and in severe cases difficulty breathing. Cytokine release syndrome is treatable, and hospital teams are experienced in managing it, but it is one of the reasons patients remain under close observation after a CAR-T infusion.

Neurological side effects — including confusion, difficulty speaking, and tremors — can also occur with some immunotherapies, though they are usually temporary. Monoclonal antibodies may cause infusion reactions during administration, and checkpoint inhibitors can trigger immune-related side effects affecting organs like the skin, liver, or thyroid. Knowing what to watch for and reporting symptoms promptly to your care team is important. For strategies on managing treatment-related symptoms, our <a href="/blog/managing-chemotherapy-side-effects-blood-cancer-guide">guide to managing chemo side effects</a> covers approaches that apply during immunotherapy as well.

Questions to Ask Your Oncologist About Immunotherapy

1. What type of immunotherapy do you recommend for my specific diagnosis, and why?
2. Am I a candidate for CAR-T cell therapy or a clinical trial involving newer immunotherapies?
3. What side effects should I expect, and how will they be managed?
4. Will I need to stay in or near the hospital during treatment, and if so, for how long?
5. How will we know if the immunotherapy is working?

When Treatment Creates Non-Medical Challenges

Immunotherapy can require extended hospital stays, frequent trips to the treatment center, and time away from work and daily responsibilities. These practical disruptions — transportation, lodging, meals, utility bills, childcare — are not medical side effects, but they are very real barriers that can interfere with a patient's ability to stay connected to care. If the logistics of treatment are becoming overwhelming, your hospital social worker can help connect you with resources designed to address these challenges.

This article is for informational purposes only and is not a substitute for professional medical advice. Always consult your oncologist or healthcare provider about your treatment options and what is right for your specific situation.